Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor ...

GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Gilead Sciences Inc. closed $6.85 short of its 52-week high ($98.90), which the company achieved on November 11th.

BofA Securities has recently resumed Gilead Sciences, Inc. (GILD) stock to Buy rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had ...

Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $91.86 which represents a decrease of $-0.52 or -0.56% from the prior close of $92.38. The stock opened at $91.66 and touched a low ...

Gilead Sciences, Inc. (GILD) and Terray Therapeutics, Inc. announced Tuesday that the companies have entered into a strategic ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential ...

(RTTNews) - Assembly Biosciences, Inc. (ASMB), Thursday announced that the company has received a total of $30.1 million from Gilead Sciences, Inc. Of the total amount, $20.1 million is an equity ...

Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy Designation ...